Regulus Therapeutics
RGLS
$2.42
Share price
6.61%
Change (1 day)
79.26%
Change (1 year)
Categories
Earnings for Regulus Therapeutics (RGLS)
Earnings in 2023 (TTM): -$29.44 M
According to Regulus Therapeutics's latest financial reports the company's current earnings (TTM) are -$29.44 M. In 2022 the company made an earning of -$27.64 M a decrease over its 2021 earnings that were of -$26.96 M.The earnings displayed on this page is the company's Pretax Income.
Earnings history for Regulus Therapeutics from 2012 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | -$29.44 M | 6.51% |
| 2022 | -$27.64 M | 2.53% |
| 2021 | -$26.96 M | 93.59% |
| 2020 | -$13.93 M | -15.41% |
| 2019 | -$16.46 M | -64.46% |
| 2018 | -$46.31 M | -33.26% |
| 2017 | -$69.38 M | -13.98% |
| 2016 | -$80.66 M | 44.77% |
| 2015 | -$55.72 M | -1.63% |
| 2014 | -$56.64 M | 203.6% |
| 2013 | -$18.66 M | 8.65% |
| 2012 | -$17.17 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $8.39 B | -28,624.53% | 🇫🇷 France |
 Biogen BIIB | $1.29 B | -4,506.09% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $8.44 B | -28,776.27% | 🇺🇸 USA |
 AstraZeneca AZN | $8.49 B | -28,963.14% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $7.53 B | -25,701.45% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | -$0.12 B | 304.29% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | -$0.12 B | 299.74% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -$0.32 B | 961.08% | 🇺🇸 USA |